On the other hand, GLP-1 receptor agonists such as liraglutide and semaglutide exert theirglucose-lowering effects through enhancement of glucose-dependent insulin secretion, delayed gastric emptying, and appetite suppression.More importantly, they have been associated with a reduction in atherosclerotic events, including myocardial infarction and stroke, inmultiple cardiovascular outcome trials [9, 10]. The gene discussed is GLP1R; the disease is stroke disorder.